Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Tiny implant conducts blood tests to track treatment

  • Comment

A tiny implant that conducts blood tests under the skin could greatly improve the tracking and treatment of cancer and other diseases, researchers claim.

The 14 millimetre-long device is packed with miniaturised electronics including five sensors and a WiFi transmitter.

Power is delivered through the skin by a battery patch which also relays test data via Bluetooth. Results can be displayed on a doctor’s mobile phone or laptop.

The sensors target proteins, sugar and organic acids in the blood that provide vital health information.

For patients with chronic illnesses, such as cancer or diabetes, the device could provide continuous monitoring and sound an alert before symptoms emerge.

Scientists believe the implant will be especially useful as a chemotherapy aid.

Currently doctors rely on occasional blood tests to assess a cancer patient’s tolerance of a particular treatment dosage. However, it is difficult to tailor the ideal dose for an individual patient.

The implant opens up the possibility of much more finely tuned and effective treatment, according to Professor Giovanni de Micheli, one of the chip designers from the EPFL polytechnic in Lausanne, Switzerland.

“It will allow direct and continuous monitoring based on a patient’s individual tolerance, and not on age and weight charts, or weekly blood tests,” said Prof de Micheli.

“In a general sense, our system has enormous potential in cases where the evolution of a pathology needs to be monitored or the tolerance to a treatment tested.”

A prototype has already been tested for five different substances and found to be as reliable as conventional analysis methods.

The results were presented today at DATE (Design Automation & Test in Europe), Europe’s largest electronics meeting taking place in Grenoble, France.

Prof de Micheli’s team hopes the device will be on the market within four years.

Sign our Speak Out Safely petition to support a transparent and open NHS. We are calling on the government to implement recommendations from the Francis report that will increase protection for staff who raise concerns about patient care.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs